Citrus polyphenol extract

Citrus Bergamot

The app lists a 3-hour half-life for citrus bergamot, modelled from citrus flavanones; naringenin from an orange extract had a half-life of about 3 hours in healthy adults.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Citrus Bergamot after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.

Drawn from the half-life in the app's model, ~3 h. The model's figures

1

Overview

Citrus bergamot is listed in the app as an oral polyphenol extract of bergamot (Citrus bergamia), with the polyphenolic fraction abbreviated BPF. The app grades the evidence as emerging, and that grade is the app's own rather than a conclusion of the sources. Gardana and colleagues, in Molecules in 2008, analysed bergamot juice from fruit harvested in Calabria, Italy, and reported naringin, neohesperidin and neoeriocitrin at 167.5, 123.9 and 73.3 mg/L, with bergamottin at 18.2 mg/L and bergapten at 9.0 mg/L.2 These are figures for juice, not for an extract product.2 The human studies identified measured blood lipids and, in some, glucose over 30 days to 6 months, and no trial with cardiovascular events as its outcome was identified in the queries run. In 2026, Chambari and colleagues rated the certainty of the pooled evidence from nine randomised trials as low to very low for all outcomes.3

In the 2011 Fitoterapia report from Mollace and colleagues, the authors wrote that bergamot juice produces lipid-lowering activity in rats "though the mechanism remains unclear".4 The same report states that BPF "inhibited HMG-CoA reductase activity", and its PubMed record does not say whether that was measured in rats, in patients or in a test system.4 The app's notes describe the HMG-flavanones brutieridin and melitidin as proposed statin-like components, based on laboratory work. In a 2017 pilot, Spigoni and colleagues reported that the characteristic HMG-containing flavanones of bergamot "were not found in plasma or urine samples despite they were selectively targeted" after three healthy adults drank bergamot juice.6 Toth and colleagues, in Frontiers in Pharmacology (volume 6, 2015), list possible mechanisms drawn from previous reports on flavonoids, including sirtuin-1 and AMPK activation and increased LDL receptor gene transcription.5 Spigoni and colleagues wrote that flavanone metabolites in circulation are "related to the cleavage of the glycoside units of the compounds present in the juice at intestinal level".6 A 2022 review by Yang and colleagues in the Journal of Nutritional Biochemistry states that "Gut microbiota plays an important role in the absorption and metabolism of naringenin and naringin".1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3 h
Bioavailability
10%
Typical dose
500–1000 mg/day
Route
Oral
Time to peak
~5 h

The app's notes state that no human pharmacokinetics exist for the whole extract and that its half-life, peak and bioavailability are modelled from citrus flavanones such as naringenin, which gut bacteria release before absorption. Queries of PubMed on 16 November 2026 for bergamot polyphenolic fraction pharmacokinetics in humans returned 2 records, a study of pancreatic cholesterol ester hydrolase and a lecithin-formulation trial, and neither title describes a pharmacokinetic study. The second column of the table holds the app's figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~3 hAbout 3 h for naringenin after 150 mg or 600 mg of naringenin from an orange extract in healthy adults; no half-life for a bergamot extract was identified1
Time to peak~5 hTmax of about 3.67 h after a single 135 mg naringenin dose in solid dispersion capsules and about 3 h after 150 mg of naringenin from an orange extract, both in healthy adults; after 400 mL of bergamot juice, plasma was sampled at 1 h and 4 h in 3 adults1,6
Bioavailability10%No figure for a bergamot extract was identified; a review states that the bioavailability of dietary flavonoids, including citrus flavanones, "is higher than previously thought" when gut microbial catabolites are counted1

Yang and colleagues also write that "The differences in ADME among pure naringenin and naringin and food sources containing naringin and naringenin have not been well studied".1 The review's authors state that all authors have no conflict of interest to declare.1 The naringenin figures come from studies of naringenin and an orange extract, so they describe those preparations and not bergamot.1

4

Human studies

The two earliest trials list authors at University Magna Graecia, Catanzaro, Italy, and the third study was run from the University of Palermo.4,7,8

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Mollace and colleagues, Fitoterapia 20114Rat study and a patient study, labelled a randomized controlled trial in PubMed; funding not stated in the record4237 patients with hyperlipemia, with or without hyperglycaemia4BPF by mouth for 30 days; the app's notes give 500 or 1000 mg/day, which the record does not4Lower total and LDL cholesterol, higher HDL, lower triglycerides and "a significant decrease in blood glucose"; no per-group figures or adverse events in the record4
Gliozzi and colleagues, International Journal of Cardiology 20137Prospective, open-label, parallel-group, placebo-controlled, 5 arms777 patients with elevated serum LDL-C and triglycerides7BPF 1000 mg/day alone (n=15) or with rosuvastatin 10 mg/day (n=15); rosuvastatin 10 or 20 mg/day (n=16 each); placebo (n=15); 30 days, oral7BPF and both rosuvastatin doses lowered total cholesterol, LDL-C, LDL-C/HDL-C ratio and urinary mevalonate against control; BPF added to rosuvastatin enhanced its effect; no numbers or adverse events in the record7
Toth and colleagues, Frontiers in Pharmacology 20155Single-group prospective study, no placebo group; registry entry NCT022055675,880 adults, mean age 55 ± 13 years, LDL-C 160 to 190 mg/dl, statin-naive; 42 (53%) with diabetes5Bergavit extract, 150 mg of flavonoids daily, oral, 6 months5LDL-C 4.6 to 3.7 mmol/l (-20%), total cholesterol 6.6 to 5.8 mmol/l, triglycerides 1.8 to 1.5 mmol/l; weight, waist and BMI changes not significant; no discontinuations and no adverse events recorded5
Spigoni and colleagues, Nutrients 20176Pilot bioavailability study of bergamot juice, one visit63 healthy adults (2 females, 1 male), mean age 38 ± 3 years6400 mL of bergamot juice once; blood at baseline, 1 h and 4 h6Up to 12 flavanone conjugates in plasma and urine; HMG-containing flavanones not found6
Sadeghi-Dehsahraei and colleagues, Phytotherapy Research 20229Systematic review and meta-analysis of randomised trials of oral bergamot in adults, random-effects model914 trials9Varied by trial9LDL-C weighted mean difference -55.43 mg/dL (95% CI -67.26 to -43.60); combined products containing bergamot gave inconsistent results; the authors call for higher-quality studies9
Chambari and colleagues, Food Science and Nutrition 20263Systematic review and meta-analysis of randomised trials of bergamot supplements39 trials; 615 participants in the LDL-C analysis3Varied by trial3Weighted mean differences against control groups: LDL-C -39.53 mg/dL (95% CI -53.46 to -25.60), with high heterogeneity among studies; glucose -12.12 mg/dL (95% CI -17.05 to -7.19); GRADE certainty low to very low3

Deeper analysis: Toth and colleagues, 6-month prospective study (2015)

Toth and colleagues gave one bergamot extract daily to 80 adults with moderate hypercholesterolemia who were naive to statin treatment, and measured them at baseline and after 6 months.5 The extract was Bergavit from Bionap, Italy, stated as 150 mg of flavonoids daily, made up of 16% neoeriocitrin, 47% neohesperidin and 37% naringin.5 After 6 months, LDL-cholesterol fell from 4.6 ± 0.2 to 3.7 ± 1.0 mmol/l, a 20% fall overall, and the authors report a stronger fall in people with higher baseline LDL-C (p = 0.004 for trend).5 Total cholesterol went from 6.6 ± 0.4 to 5.8 ± 1.1 mmol/l, triglycerides from 1.8 ± 0.6 to 1.5 ± 0.9 mmol/l (p = 0.0020) and HDL-C rose from 1.3 ± 0.2 to 1.4 ± 0.4 mmol/l (p = 0.0007).5 Carotid intima-media thickness fell from 1.2 ± 0.4 to 0.9 ± 0.1 mm, and small, dense LDL-3, LDL-4 and LDL-5 decreased by 38, 53 and 67%.5 Not every measure moved: LDL-2 changed by -3% (p = 0.4428), VLDL particles showed no significant difference, and large, medium and small IDL increased.5 Body weight, waist circumference and body mass index "slightly improved", but "the differences did not achieve the statistical significance".5 The paper's results do not report a glucose outcome, although 42 of the 80 participants (53%) had diabetes at baseline.5 For safety, the authors write that "None of them had to discontinue the supplementation and no adverse events were recorded".5 The authors name "the absence of a control (placebo) group" as a potential limitation, so the changes are before-and-after differences within one group, tested with a paired t-test.5 The registry entry lists the University of Palermo as lead sponsor, a completed status with a start in June 2014 and an observational, case-only model.8 The same entry names two groups, 500 mg/day and 1000 mg/day of a bergamot-derived product, and an enrolment of 160, which differs from the paper's single dose and 80 people.8,5 The analyses of the extract's flavanones were carried out by Bionap, whose data the authors thank in their acknowledgements.5 The authors declare "the absence of any commercial or financial relationships that could be construed as a potential conflict of interest", and add that they "have given talks, attended conferences and participated in advisory boards and trials sponsored by various pharmaceutical companies".5 The acknowledgements state that part of the work used instruments provided by the Euro-Mediterranean Institute of Science and Technology and funded with the Italian National Operational Programme for Research and Competitiveness 2007–2013 grant, and that the authors did not receive financial or professional help with the preparation of the manuscript.5

Deeper analysis: Mollace and colleagues, Fitoterapia (2011)

Mollace and colleagues, at the Faculty of Pharmacy, University Magna Graecia, Catanzaro, tested a bergamot extract (BPF) in diet-induced hyperlipemia in Wistar rats and in 237 patients with hyperlipemia, with or without hyperglycaemia.4 BPF was given orally for 30 days, and the authors report lower total and LDL cholesterol with higher HDL, lower triglycerides and "a significant decrease in blood glucose".4 The PubMed record read for this study gives no group sizes, doses, adverse events, funding statement, author ties or limitations, and the full text was not available for reading.4

Deeper analysis: Gliozzi and colleagues, rosuvastatin trial (2013)

Gliozzi and colleagues randomly assigned 77 patients with elevated LDL-C and triglycerides to placebo (n=15), rosuvastatin 10 mg/day (n=16), rosuvastatin 20 mg/day (n=16), BPF 1000 mg/day (n=15) or BPF 1000 mg/day plus rosuvastatin 10 mg/day (n=15), each for 30 days.7 The design is described as open-label, and the record lists the work as supported by a non-US-government source without naming it.7 Reductions in malondialdehyde, the oxyLDL receptor LOX-1 and phosphoPKB were reported alongside the lipid changes, and the authors conclude that BPF added to rosuvastatin "significantly enhanced" its effect on the serum lipid profile.7 The PubMed record read gives no numeric results, adverse events, limitations or conflict statement, and the full text was not available for reading; Mollace, the first-listed author of the 2011 report, is the last-listed author.7,4

Deeper analysis: the 2026 meta-analysis of randomised trials

Chambari and colleagues pooled randomised trials of bergamot supplements in adults with dyslipidemia or metabolic syndrome, with LDL-C pooled over nine studies, 14 arms and 615 participants.3 Pooled differences were -39.53 mg/dL for LDL-C and -12.12 mg/dL for glucose, and the authors report "very large variability in true effects across studies" for glucose.3 Some outcomes showed no effect: for BMI "no significant effect was observed", and bergamot did "not exhibit a significant effect on GGT in comparison with the control group".3 Risk of bias was rated poor in six trials, fair in two and good in one.3 The authors write that the observed effects "are mainly based on very-low-certainty evidence, largely from studies at high risk of bias", and the funding statement reads "The authors have nothing to report".3 Egger's test suggested potential small-study effects for glucose, and the authors list as a limitation that all included trials were conducted in Italy and China.3 In the conflicts statement, Ali Jafari is listed as holding an editorial position at Systematic Reviews, and the other authors declare no relevant financial or non-financial interest.3 Sadeghi-Dehsahraei and colleagues, in Phytotherapy Research in 2022, pooled 14 trials and also noted that findings for combined nutraceuticals containing bergamot were inconsistent; only its PubMed record was available for reading, so its funding and limitations are not described here.9

Deeper analysis: Spigoni and colleagues, bergamot juice bioavailability pilot (2017)

Spigoni and colleagues gave three healthy adults 400 mL of bergamot juice after an overnight fast and took blood at baseline, 1 h and 4 h.6 They identified up to 12 flavanone conjugates, with plasma concentrations from 0.11 to 3.54 μM for the main ones, and variability between volunteers averaging 23% at 1 h and 69% at 4 h.6 The authors call the variability data "of preliminary nature, considering the low number of subjects involved in this study".6 They state that longer periods, up to 24 or 48 hours, remain to be assessed in later bioavailability studies.6 In cells, some circulating glucuronides modulated inflammation but none was effective against stearate-induced lipoapoptosis; that is a cell result, not a result in people.6 The study was funded by the Rural Development Program of Calabria Region, Italy (Measure 124), with the project leader named as UNIONBERG OP, and the authors declare no conflict of interest.6

5

Doses reported in studies and on labels

A DailyMed query for bergamot returned 35 labels; the first 20 listed were cosmetic, hygiene or fragrance products, and no label for a bergamot extract was identified among those 20. The table lists study doses; the naringenin rows are comparators from citrus preparations other than bergamot.

Table 5.1Doses reported in studies and on labels8 rows
SourcePreparation and routeDoseLengthPeople and comparator
The app's typical rangeOral500 to 1000 mg/dayNot statedNot applicable; the app's figure
Mollace and colleagues 20114BPF, oralNot stated in the PubMed record30 days237 patients; comparator not described in the record
Gliozzi and colleagues 20137BPF, oral1000 mg/day, alone or with rosuvastatin 10 mg/day30 days77 patients across 5 arms; placebo (n=15) and rosuvastatin arms
Toth and colleagues 20155Bergavit extract, oral150 mg of flavonoids daily6 months80 adults; no comparator group
NCT02205567 registry entry8Bergamot-derived product, dietary supplement500 mg/day (group 1) and 1000 mg/day (group 2)Baseline and 6 monthsEnrolment 160; case-only observational model
Spigoni and colleagues 20176Bergamot juice, oral400 mL onceSingle visit3 healthy adults; no comparator
Naringenin pharmacokinetics (not bergamot)1Naringenin, oral135 mg single dose; 150 mg or 600 mg of naringenin from an orange extractSingle doseHealthy adults
Naringenin safety trial (not bergamot)1Orange extract, oral150 mg to 900 mg naringeninSingle ascending doses18 participants, randomised and placebo-controlled

In Toth and colleagues' 80 adults on Bergavit for 6 months, "no adverse events were recorded" and no one discontinued the supplement.5 The PubMed records read for Mollace and colleagues (2011) and Gliozzi and colleagues (2013) report no adverse event figures.4,7 In the naringenin trial of 18 participants described by Yang and colleagues, doses of 150 mg to 900 mg naringenin from an orange extract "had no adverse events"; the review says it may need repeating with larger samples, and the trial did not use bergamot.1 The app's notes say bergamot contains bergamottin, a grapefruit-type CYP3A4 inhibitor, in unstated amounts. Gardana and colleagues measured bergamottin at 18.2 ± 0.5 mg/L in a bergamot juice and noted that this was lower than amounts reported in the literature.2 He and colleagues, in Chemical Research in Toxicology in 1998, reported that bergamottin, "the primary furanocoumarin extracted from grapefruit juice, is a mechanism-based inactivator of P450 3A4" in a reconstituted system of purified enzyme.10 The same record states that "Grapefruit juice has been found to significantly increase oral bioavailability of several drugs metabolized by cytochrome P450 3A4".10 Queries of PubMed on 16 November 2026 for bergamot with CYP3A4, and for bergamot drug interaction with cytochrome P450 and CYP3A4 inhibition, returned 0 records, and no clinical interaction study of a bergamot extract was identified. For pregnancy, a PubMed query for bergamot and pregnancy returned 1 record, on inhaled bergamot essential oil in a hormone-simulated pseudopregnancy model, and the app's notes state that there are no pregnancy data.

The app lists lipids and fasting glucose as the markers to monitor. Toth and colleagues drew serum after a 14 h overnight fast and measured total cholesterol, triglycerides, HDL-C, calculated LDL-C by the Friedewald formula, lipoprotein subclasses and carotid intima-media thickness.5 Mollace and colleagues reported lipid and blood glucose changes, and Gliozzi and colleagues also measured urinary mevalonate, malondialdehyde, LOX-1 and phosphoPKB.4,7 In the 2026 meta-analysis, pooled HOMA-IR fell by 0.38 units (95% CI -0.65 to -0.11) across three trials with 5 arms, and the authors rated GRADE certainty very low for all outcomes except waist circumference.3

8

Regulatory and anti-doping status

The app lists citrus bergamot as not WADA prohibited. The text of the WADA 2026 Prohibited List does not mention bergamot, Citrus or flavonoid in the copy read.11 Only DailyMed was queried for regulator documents; of the 35 labels returned for bergamot, the first 20 listed were cosmetic, hygiene or fragrance products, and no label or assessment of a bergamot extract was identified among those 20.

No human pharmacokinetic study of a bergamot extract was identified, so the app's 3 h half-life, 5 h peak and 10% bioavailability are modelled from citrus flavanones. The doses behind the trials are not aligned: the paper by Toth and colleagues states 150 mg of flavonoids daily, while the registry entry for the same study lists 500 and 1000 mg/day.5,8 Whether the proposed statin-like HMG-flavanones reach the blood in people is not settled: they were not found after bergamot juice in a pilot of three adults, which sampled to 4 hours.6 The authors of the juice pilot state that randomised controlled studies with bergamot juice or extract on recognised markers of cardiovascular health are needed.6 The amount of bergamottin in extract products, and whether it changes the exposure to any medicine in people, is not stated in the sources read. No trial with cardiovascular events as its outcome was identified, and the app's notes state that there are no outcome trials.

What is the half-life of citrus bergamot?

The app lists a half-life of about 3 hours for citrus bergamot, modelled from citrus flavanones. Naringenin from an orange extract had a half-life of about 3 hours in healthy adults, and no half-life for a bergamot extract was identified.1

How long does bergamot take to reach its peak level?

The app lists about 5 hours to peak. Naringenin reached its maximum concentration at about 3.67 hours after 135 mg and about 3 hours after 150 mg from an orange extract in healthy adults.1

What is the bioavailability of citrus bergamot?

The app lists 10%, and no figure for a bergamot extract was identified. A review states that the bioavailability of dietary flavonoids, including citrus flavanones, is higher than previously thought when gut microbial catabolites are counted.1

Is bergamot extract banned by WADA?

The app lists citrus bergamot as not WADA prohibited. The 2026 Prohibited List text read does not mention bergamot, Citrus or flavonoid.11

Does bergamot lower LDL cholesterol?

In a 6-month single-group study of 80 adults, LDL-cholesterol fell from 4.6 ± 0.2 to 3.7 ± 1.0 mmol/l, and the study had no placebo group.5 A 2026 meta-analysis pooled a weighted mean difference of -39.53 mg/dL in LDL-C against control groups, with high heterogeneity among studies, but rated the certainty of evidence low to very low and wrote that the observed effects are mainly based on very-low-certainty evidence.3

Does bergamot lower blood glucose?

The 2026 meta-analysis pooled a glucose difference of -12.12 mg/dL (95% CI -17.05 to -7.19), with very large variability in true effects across studies and very low certainty.3 The 6-month study by Toth and colleagues reports no glucose result.5

Does bergamot contain a grapefruit-type CYP3A4 inhibitor?

Bergamot juice contained bergamottin at 18.2 ± 0.5 mg/L in one analysis, and the app's notes say extracts contain it in unstated amounts.2 Bergamottin inactivated P450 3A4 in a purified-enzyme system, and no clinical interaction study of a bergamot extract was identified.10

What is in the Bergavit extract used in the Toth study?

The extract was stated as 150 mg of flavonoids, made up of 16% neoeriocitrin, 47% neohesperidin and 37% naringin.5

Is there outcome evidence for citrus bergamot?

No trial with cardiovascular events as its outcome was identified in the queries run, and the app's notes state that there are no outcome trials.

Is there pregnancy data for bergamot extract?

The app's notes state that there are no pregnancy data. A PubMed query for bergamot and pregnancy returned 1 record, on inhaled bergamot essential oil in a pseudopregnancy model.

12

References

  1. Yang Y, et al. Beneficial effects of citrus flavanones naringin and naringenin and their food sources on lipid metabolism: an update on bioavailability, pharmacokinetics, and mechanisms. J Nutr Biochem 2022. PMC9058202
  2. Gardana C, et al. Evaluation of flavonoids and furanocoumarins from Citrus bergamia (bergamot) juice and identification of new compounds. Molecules 2008. PMC6244945
  3. Chambari M, et al. Bergamot (Citrus bergamia) supplementation and cardiovascular disease risk factors: a systematic review and meta-analysis. Food Sci Nutr 2026. PMC13575982
  4. Mollace V, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia 2011. PMID 21056640
  5. Toth PP, et al. Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: a 6 months prospective study. Front Pharmacol 2015;6:299. PMC4702027
  6. Spigoni V, et al. Bioavailability of bergamot (Citrus bergamia) flavanones and biological activity of their circulating metabolites in human pro-angiogenic cells. Nutrients 2017. PMC5748778
  7. Gliozzi M, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol 2013. PMID 24239156
  8. University of Palermo. Bergamot and Cardio-Metabolic Risk Factors. ClinicalTrials.gov NCT02205567. NCT02205567
  9. Sadeghi-Dehsahraei H, et al. The effect of bergamot (KoksalGarry) supplementation on lipid profiles: a systematic review and meta-analysis of randomized controlled trials. Phytother Res 2022. PMID 36251526
  10. He K, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998. PMID 9548795
  11. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list